美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Emera Inc.

46.07

+0.30000.66%

盘后：46.070.00000.00%16:37 EDT

成交量：6.74万

成交额：309.64万

市值：137.24亿

市盈率：22.27

高：46.08

开：45.76

低：45.51

收：45.77

数据加载中...

总览公司新闻公告

诺和诺德宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理用于体重管理。此次上市申请是基于III期STE

诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理

【诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理】智通财经APP获悉，7月8日，诺和诺德(NVO.US

Pi币强势回归？Pi网络借助Zypto整合冲击DeFi　能否迎来全面反弹？

技术分析：美元表现不佳，美元/加元面临抛售压力

【葛兰素史克(GSK.US)口服靶向新药“利奈昔巴特片”在中国拟纳入优先审评】智通财经APP获悉，7月4日，中国国家药监

药明合联新加坡基地达成机械完工里程碑，加速生物偶联药全球化布局

Bitget链上交易（Onchain）产品更新，全面优化止盈止损模块

XRP 价格预测：重大“突破”预计 90 天内发生　XRP 有望飙至 $589？

突破通用领域推理的瓶颈！清华NLP实验室强化学习新研究RLPR

乐普生物：EGFR ADC联合PD-1单抗IND申请获EMA批准

生物药大时代

港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知

【港股异动 | 海普瑞(09989.HK)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知】智通

【湾区早参】深圳二手房在售量超过72000套；广州发布智能网联汽车发展计划

首个三期临床99.9%有效艾滋预防药在美获批，吉利德：期待尽快带到中国

XRP牛市起点？监管胜利是否足以引爆300%涨幅？

百奥泰：乌司奴单抗注射液获欧洲药品管理局人用药品委员会积极意见

一年两针！吉利德突破性长效HIV疗法获FDA批准上市

海普瑞(002399.SZ)：依诺肝素钠注射液获得EMA新增生产商批准

分析师：比特币 50 日与 200 日移动均线差距拉大确认中期看涨前景

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/EMA/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EMA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":46.07,"timestamp":1752264000000,"preClose":45.77,"halted":0,"volume":67429,"hourTrading":{"tag":"盘后","latestPrice":46.07,"preClose":46.07,"latestTime":"16:37 EDT","volume":4372,"amount":201606.769565,"timestamp":1752266233156},"delay":0,"floatShares":297630102,"shares":297900000,"eps":2.069006,"marketStatus":"休市中","change":0.3,"latestTime":"07-11 16:00:00 EDT","open":45.76,"high":46.08,"low":45.51,"amount":3096390.9260400003,"amplitude":0.012454,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.069006,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":45.77,"dividendRate":0.046003,"postHourTrading":{"tag":"盘后","latestPrice":46.07,"preClose":46.07,"latestTime":"16:37 EDT","volume":4372,"amount":201606.769565,"timestamp":1752266233156},"volumeRatio":0.9257316863484103,"impliedVol":0,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EMA\",,,,,undefined,":{"symbol":"EMA","floatShares":297630102,"roa":"2.73%","roe":"7.21%","lyrEps":1.186627,"volumeRatio":0.9257316863484103,"shares":297900000,"dividePrice":2.105917,"high":46.08,"amplitude":0.012454,"preClose":45.77,"low":45.51,"week52Low":43.9012,"pbRate":"1.53","psRate":"2.39","week52High":46.45,"institutionHeld":0,"latestPrice":46.07,"eps":2.069006,"divideRate":0.045711,"volume":67429,"delay":0,"ttmEps":2.069006,"open":45.76,"prevYearClose":45.28,"prevWeekClose":45.49,"prevMonthClose":45.82,"prevQuarterClose":45.82,"fiveDayClose":45.49,"twentyDayClose":44.33,"earningDate":1754582400000,"earningTime":"盘前"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EMA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550029687","title":"诺和诺德宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理用于体重管理。此次上市申请是基于III期STE","url":"https://stock-news.laohu8.com/highlight/detail?id=2550029687","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550029687?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 17:15","pubTimestamp":1752052556,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK4599","BK4007","UP","IE00BZ1G4Q59.USD","STEP","BK4135","LU0154236417.USD","BK4532","BK4081","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","BK4008","BK4585","BK4588","EMA","NVO","BK4134"],"gpt_icon":0},{"id":"2550681411","title":"诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681411","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550681411?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月8日，诺和诺德(NVO.US)宣布7.2mg司美格鲁肽的上市申请获得欧洲药品管理局(EMA)受理，用于体重管理。此次上市申请是基于III期STEP UP研究和III期STEP UP T2D研究的积极结果。结果显示，患者平均基线体重为113kg，治疗第72周，7.2mg司美格鲁肽组、2.4mg司美格鲁肽组和安慰剂组患者的体重分别减轻了20.7%、17.5%和2.4%。此外，7.2mg司美格鲁肽组有33.2%的患者实现了体重减轻25%以上的效果，而2.4mg司美格鲁肽组和安慰剂组的这一比例分别为16.7%和0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4532","LU0154236417.USD","BK4081","BK4588","NVO","EMA","LU1093756168.USD","BK4007","BK4585","BK4599","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2550681251","title":"【诺和诺德(NVO.US)7.2mg司美格鲁肽上市申请获EMA受理】智通财经APP获悉，7月8日，诺和诺德(NVO.US","url":"https://stock-news.laohu8.com/highlight/detail?id=2550681251","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550681251?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 16:21","pubTimestamp":1752049283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UP","BK4008","BK4134","BK4585","IE00BKVL7J92.USD","BK4588","BK4007","BK4135","STEP","EMA","LU1093756325.SGD","BK4532","BK4599","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","NVO","BK4081","III"],"gpt_icon":0},{"id":"2549349705","title":"Pi币强势回归？Pi网络借助Zypto整合冲击DeFi　能否迎来全面反弹？","url":"https://stock-news.laohu8.com/highlight/detail?id=2549349705","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549349705?lang=zh_cn&edition=fundamental","pubTime":"2025-07-05 13:00","pubTimestamp":1751691600,"startTime":"0","endTime":"0","summary":"\n                                        \n去中心化支付应用 Zypto 已在其移动平台上线 Pi币（PI） 支持，意味着“先锋者”（Pioneers）现在可以通过其实体与虚拟 VISA卡，将持有的资产用于日常消费支付。\n\n\n\n随着这一新场景的落地，Pi币的价格预测展现出强烈看涨信号。截至撰写时，Zypto 支付应用已覆盖 10 多个国家，支持超过 24,000 种加密资产交易与支付，为 Pi 币打开了更广泛的实用性与主流采纳空间。\n\n\n\n\n\n\n\n此外，Zypto 还推出了一款基于 Pi 的去中心化应用（dApp），具备跨链互操作能力，用户可通过该应用将 Pi 代币兑换为其他加密资产，进一步拓展了 Pi 的资产流动性与 DeFi 融合度。\n\n\n\n这一消息发布的时间点正值 “Pi 日”活动后不久。该活动由开发团队举办，旨在向社区介绍若干新功能与生态进展。\n\n\n\n尽管 Pi 公链主网已于 2 月上线，但其生态建设进展缓慢，一度引发市场质疑。而本次与 Zypto 的深度集成，被视为激活生态发展的关键一步，有望在 Pi...                                    ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/pi-coin-price-prediction-pi-network-gains-defi-momentum-with-zypto-integration-is-a-full-recovery-on-the-table/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["PI","BTC.USD.HKCC","03008","BK4594","09042","09439","03042","BK1611","BTCmain","EMA","BK4081","BK4141","BK4601","83042","09008","03439","MBTmain","BK4585","XBTmain","LU1878469433.USD","BTC.USD.CC","BK4588"],"gpt_icon":1},{"id":"2548239816","title":"技术分析：美元表现不佳，美元/加元面临抛售压力","url":"https://stock-news.laohu8.com/highlight/detail?id=2548239816","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548239816?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 18:21","pubTimestamp":1751624460,"startTime":"0","endTime":"0","summary":"虽然短时内美元/加元有所反弹，美元/加元仍面临抛售压力，美元回吐了昨日非农数据公布后的大部分涨幅。特朗普的巨额法案在共和党控制的众议院通过，预计这将使财政债务增加超过3万亿美元。由于7月9日关税截止日期的不确定性，加元的表现逊于其他同行。技术分析技术指标明确指向下方，预示着可能跌破6月低点1.3539，延续下行趋势。总之，美元/加元目前的看跌阶段似乎还有更多下行空间，可能在1.3460附近形成新的低点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/forex-news/article-2873023","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["BK4081","EMA"],"gpt_icon":0},{"id":"2548330995","title":"【葛兰素史克(GSK.US)口服靶向新药“利奈昔巴特片”在中国拟纳入优先审评】智通财经APP获悉，7月4日，中国国家药监","url":"https://stock-news.laohu8.com/highlight/detail?id=2548330995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548330995?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 10:44","pubTimestamp":1751597061,"startTime":"0","endTime":"0","summary":null,"market":"uk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1202635105.USD","LU0225284248.USD","CDE.AU","LU1645745479.HKD","IE00BWDBJ516.SGD","LU1670756490.USD","GSK","LU0321505439.SGD","LU0306806265.USD","IBAT","LU1228905037.USD","CDE","LU1064927863.SGD","LU0058720904.USD","BK7050","IE0034235071.USD","LU0225771236.USD","LU0971552830.HKD","LU1228905540.USD","BK4585","BK4017","LU0203345920.USD","LU1487256676.USD","LU0971552673.USD","LU0321505868.SGD","LU0545562505.USD","LU1046248800.SGD","LU1481600234.SGD","LU1829250122.USD","LU1400636574.HKD","EMA","LU1015430645.USD","LU1400636657.SGD","LU1481599808.USD","LU1223082519.USD","BK4007","LU1400636491.USD","BK5011","LU0211331839.USD","LU0575583348.USD","LU1098665638.USD","LU1223082196.USD","LU0289739699.SGD","LU1223083913.SGD","LU1302929846.USD","PBC","LU0985481810.HKD","LU1035777561.USD","GSK.UK","BK4588"],"gpt_icon":0},{"id":"2548465885","title":"药明合联新加坡基地达成机械完工里程碑，加速生物偶联药全球化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2548465885","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548465885?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 17:34","pubTimestamp":1751362440,"startTime":"0","endTime":"0","summary":"中国上海和新加坡 2025年7月1日 /美通社/ -- 6月30日，全球领先的生物偶联药物合同研究、开发和生产企业药明合联欣然宣布，其位于新加坡大士生物医药园的生产基地正式完成机械完工，这一里程碑事件标志着这座总建筑面积约25,000平方米的生产基地将全面进入设备及设施调试和验证阶段。作为药明合联全球化战略的重要部署，新加坡基地建设秉承公司无锡基地的\"完美执行\"理念和\"药明速度\"，皆在为客户打造敏捷、灵活的一站式解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4722094_ZH22094_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ADC","EMA","BK4231","BK4081","BK1141","SG9999014674.SGD","LU2488822045.USD","02268","BK4080"],"gpt_icon":0},{"id":"2547006394","title":"Bitget链上交易（Onchain）产品更新，全面优化止盈止损模块","url":"https://stock-news.laohu8.com/highlight/detail?id=2547006394","media":"Odaily","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547006394?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 16:19","pubTimestamp":1751271580,"startTime":"0","endTime":"0","summary":"Odaily星球日报讯 据官方消息，Bitget 对其链上交易（Onchain）产品进行多项优化，以全面提升用户交易体验，更新 Bitget App 至最新版本即可体验。本次升级主要包括：\n止盈止损功能升级：可一键预设止盈/止损，助力掌握交易节奏\n交易指标功能更新：新增 EMA、RSI 等多项专业数据，精准分析行情\n当前委托订单功能优化：支持查看滑点、金额等详情，全面掌握交易信息\n新手专属教程上线：可轻松查看操作教程，便于快速上手交易\nPIN 码功能全新上线：下单时多重防护，守护资金安全\n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.odaily.news/newsflash/436855?source=share","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"odaily_live","symbols":["RSI","BK4150","BK4081","EMA"],"gpt_icon":0},{"id":"2546953617","title":"XRP 价格预测：重大“突破”预计 90 天内发生　XRP 有望飙至 $589？","url":"https://stock-news.laohu8.com/highlight/detail?id=2546953617","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546953617?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 13:00","pubTimestamp":1751000400,"startTime":"0","endTime":"0","summary":"\n在周末跌破 $1.90 后，XRP（XRP）正悄悄重新获得市场关注，随着地缘政治新闻改变市场情绪，其价格开始回升。\nXRP 曾短暂跌破心理关口 $2，但在美国前总统川普介入调停伊朗与以色列之间的停火后，买盘迅速回流，带动价格反弹。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-prediction-major-breakout-predicted-within-90-days-589-xrp-possible/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["BK4585","03008","BK4588","BK4594","09042","83042","03439","03042","09439","MBTmain","BK4601","BK4081","EMA","09008","BTC.USD.CC","BK1611","BTC.USD.HKCC"],"gpt_icon":1},{"id":"2546642507","title":"突破通用领域推理的瓶颈！清华NLP实验室强化学习新研究RLPR","url":"https://stock-news.laohu8.com/highlight/detail?id=2546642507","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546642507?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 10:30","pubTimestamp":1750991400,"startTime":"0","endTime":"0","summary":"针对这一关键挑战，清华大学自然语言处理实验室提出了一项关键性技术 —— 基于参考概率奖励的强化学习。同时，RLPR 提出基于奖励标准差的动态过滤机制，进一步提升强化学习的稳定性和性能提升。目前 RLPR 相关代码、模型、数据、论文均已开源。结果表明，PR 在 0.5B 规模即取得了显著优于规则奖励和验证器模型奖励的质量。RLPR 在 Gemma、Llama、Qwen 等不同基座模型上均稳定提升推理能力总结RLPR 提出了创新的 Prob-to-Reward 奖励机制，解决了现有 RLVR 范式的领域依赖问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-27/doc-infcnrzr2751855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081","BK4588","BK4202","BK4585","RL","LU0006061336.USD"],"gpt_icon":0},{"id":"2546275727","title":"乐普生物：EGFR ADC联合PD-1单抗IND申请获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2546275727","media":"生物药大时代","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546275727?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 09:45","pubTimestamp":1750902347,"startTime":"0","endTime":"0","summary":"2025年6月24日，乐普生物科技股份有限公司的MRG003联合普特利单抗对比MRG003单药治疗局部晚期头颈鳞癌的II期研究的临床试验申请获得欧洲药品管理局批准，计划将于2025Q3启动入组。该研究是全球首个EGFR ADC联合PD-1单抗在局晚期头颈鳞癌的临床研究。EGFR ADC与普特利单抗联合治疗在EGFR阳性实体瘤患者中具有良好的耐受性和令人鼓舞的抗肿瘤活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094830a71df665&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02157","EMA"],"gpt_icon":0},{"id":"2545847686","title":"港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545847686?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海普瑞午前涨超3%，截至发稿，涨3.09%，报5.33港元，成交额872.01万港元。消息面上，海普瑞发布公告，公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍，海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三条预灌封生产线设计产能为3.3亿支╱年，其按照中国、欧美药品法规标准设计建造，用于生产依诺肝素钠预灌封注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","BK0239","BK0188","BK1191","EMA","BK0070","09989","002399"],"gpt_icon":0},{"id":"2545476550","title":"【港股异动 | 海普瑞(09989.HK)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知】智通","url":"https://stock-news.laohu8.com/highlight/detail?id=2545476550","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545476550?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0239","BK0070","BK0188","BK1191","BK4081","EMA","09989","002399"],"gpt_icon":0},{"id":"2545299104","title":"【湾区早参】深圳二手房在售量超过72000套；广州发布智能网联汽车发展计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2545299104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545299104?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 08:28","pubTimestamp":1750724898,"startTime":"0","endTime":"0","summary":"主要原因为：集团铝合金产品及氧化铝产品销售价格均较2024年同期上涨，销售数量亦有所增加。mCRPC为晚期前列腺癌的一种，属对去势治疗产生耐药并可能出现新转移的病症。此次于美的威灵量产的产品为该集团Gen3.0高压700V半桥氮化镓芯片产品。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960965","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","CCA","02617","BK1594","SG9999001093.SGD","SG9999014674.SGD","LU0702159699.USD","02338","BK4081","LU0737861699.HKD","BK1592","BK1171","SG9999006597.SGD","01378","LU1166156734.SGD","IE0034224299.USD","BK1163","01497","BK1522","LU1224709979.USD","BK1175","EMA","BK1237","LU1808992512.USD","LU0287142896.SGD","BK1500","LU0173614495.USD","02533","02577"],"gpt_icon":1},{"id":"2545250490","title":"首个三期临床99.9%有效艾滋预防药在美获批，吉利德：期待尽快带到中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2545250490","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545250490?lang=zh_cn&edition=fundamental","pubTime":"2025-06-23 17:58","pubTimestamp":1750672684,"startTime":"0","endTime":"0","summary":"研究数据显示，在3期临床研究PURPOSE 1 和 PURPOSE 2 中，超过99.9%接受 Yeztugo的受试者保持HIV 检测阴性。吉利德中国向蓝鲸新闻表示，来那帕韦用于HIV预防已在美国获批，目前，在其他国家或地区都尚未获批。我们正在和政府、卫生部门及监管机构密切沟通，期待尽快将这一革新的HIV预防方案带到中国，帮助加速国内的HIV防控进程。“Yeztugo一年仅需给药两次，在临床研究中展现出了卓越效果，这意味着它有可能革新HIV 的预防格局。”抗HIV一直是吉利德科学的业务核心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1750672598921205915","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4585","BK4081","MAA","BK4215","BK4588","EMA"],"gpt_icon":0},{"id":"2545438934","title":"XRP牛市起点？监管胜利是否足以引爆300%涨幅？","url":"https://stock-news.laohu8.com/highlight/detail?id=2545438934","media":"cryptonews","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545438934?lang=zh_cn&edition=fundamental","pubTime":"2025-06-22 09:00","pubTimestamp":1750554000,"startTime":"0","endTime":"0","summary":"\nXRP目前稳固运行在2美元上方，目前交易价格约为2.13美元，自2024年11月反弹前低点以来，涨幅已超过300%。然而，市场正显现出整理迹象。在2.15美元阻力位附近出现了一个看跌吞没形态，同时还有下降趋势线，表明卖压正在增强。50周期指数移动平均线（EMA）同样位于2.15美元附近，进一步强化了该价位作为技术阻力的意义。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cryptonews.com/cn/news/xrp-price-analysis-can-regulatory-wins-sustain-the-rally-beyond-300/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"cryptonews_cn_highlight","symbols":["EMA","FDN","BK4550","BK4585","BK4081","BK4588"],"gpt_icon":0},{"id":"2544014999","title":"百奥泰：乌司奴单抗注射液获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2544014999","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544014999?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 16:05","pubTimestamp":1750406759,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)公告，公司近日收到了欧洲药品管理局(简称“EMA”)的通知，Usymro®(BAT2206，乌司奴单抗注射液)获得EMA人用药品委员会(简称“CHMP”)积极意见。CHMP建议欧盟委员会(EC)批准Usymro®上市，用于治疗成人及儿童的：中重度斑块状银屑病(PsO)，活动性银屑病关节炎(PsA)，中重度活动性克罗恩病(CD)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201609209787a9de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506201609209787a9de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EC","BK4081","BK4116","BK4201","EMA","CD"],"gpt_icon":0},{"id":"2544194287","title":"一年两针！吉利德突破性长效HIV疗法获FDA批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2544194287","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544194287?lang=zh_cn&edition=fundamental","pubTime":"2025-06-20 07:31","pubTimestamp":1750375894,"startTime":"0","endTime":"0","summary":"4吉利德深耕HIV领域吉利德科学公司在HIV治疗和预防领域拥有超过35年的创新经验。吉利德致力于通过科学创新提供满足HIV患者不断变化需求的解决方案。通过与全球健康倡导者和组织的合作，吉利德还旨在改善教育、扩大药物可及性，并解决护理障碍，目标是终结全球HIV流行。这种每年仅需注射两次的长效方案有望显著提高患者的依从性，降低HIV传播风险，推动全球HIV预防目标的实现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620073702a7135975&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3B42.SGD","BK4215","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU1674673691.USD","BK4081","LU0320765992.SGD","BK4566","BK4583","GILD","LU0234570918.USD","EMA","LU2087621335.USD","BK4550","LU1839511570.USD","IE0002270589.USD","IE00BKVL7J92.USD","LU1585245621.USD","LU2468319806.SGD","MAA","LU0289739699.SGD","LU1066051498.USD","BK4585","BK4139","BK4588","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU0823416689.USD","LU1430594728.SGD","LU1778281490.HKD","LU0058720904.USD","BK4532","LU1571399168.USD","IE00B3T34201.USD","BK4568","LU1674673428.USD","IE00BSNM7G36.USD","LU0109394709.USD","LU2089984988.USD","BK4578"],"gpt_icon":0},{"id":"2544549439","title":"海普瑞(002399.SZ)：依诺肝素钠注射液获得EMA新增生产商批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2544549439","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544549439?lang=zh_cn&edition=fundamental","pubTime":"2025-06-17 16:51","pubTimestamp":1750150299,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(002399.SZ)发布公告，公司近日收到欧洲药品管理局(“EMA”)签发的关于依诺肝素钠注射液新增成品制造商的批准通知。本次公司坪山园区预灌封制剂生产线获得EMA的许可，标志着公司坪山园区生产的依诺肝素钠注射液已获得在欧洲经济区(EEA)实现商业化的资格，本次获批将为公司进一步推进制剂国际化战略提供更加充足的产能保障，切实提高公司市场竞争力;同时，依托强大的预灌针生产能力，以及公司成熟的自营销售网络及渠道，公司助力中国药企药品出海欧美市场的战略将得到有力的支持和推动，对公司未来业务拓展有深远且积极的影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","BK1191","BK0239","002399","BK0188","09989","BK0070","BK4081"],"gpt_icon":0},{"id":"2542517833","title":"分析师：比特币 50 日与 200 日移动均线差距拉大确认中期看涨前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2542517833","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542517833?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 09:00","pubTimestamp":1749517214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7485739","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["BTC.USD.CC","MBTmain","03008","09008","BK4601","BK1611","83042","BK4594","09439","EMA","BK4588","03439","03042","09042","MSTU","BTC.USD.HKCC","BK4081","IBIT","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EMA\",params:#limit:5,,,undefined,":[{"date":"2025-08-08","symbol":"EMA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1754640000000,"name":null,"time":"盘前","dateTimestamp":1754625600000,"actualEps":null},{"date":"2025-08-01","symbol":"EMA","amount":0.725,"announcedDate":"2025-07-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-01","defaultRemindTime":1754055000000,"name":"Emera Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-15","payableDate":"2025-08-01","currency":"CAD","dateTimestamp":1754020800000,"payDate":"2025-08-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EMA\",market:\"US\",,,undefined,":[{"executeDate":"2015-07-29","recordDate":"2015-07-31","paymentDate":"2015-08-17","value":0.305564,"currency":"USD"},{"executeDate":"2015-10-29","recordDate":"2015-11-02","paymentDate":"2015-11-16","value":0.3565682,"currency":"USD"},{"executeDate":"2016-01-29","recordDate":"2016-02-02","paymentDate":"2016-02-16","value":0.3421147,"currency":"USD"},{"executeDate":"2016-04-28","recordDate":"2016-05-02","paymentDate":"2016-05-16","value":0.3682105,"currency":"USD"},{"executeDate":"2016-07-20","recordDate":"2016-07-22","paymentDate":"2016-08-15","value":0.4045038,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EMA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0667,"buy":0.4,"hold":0.4667,"sell":0,"strongSell":0.0667,"meanLabel":"HOLD","meanPercent":0.4667,"analysts":15,"updateTime":1750996800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EMA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EMA","date":"2025-07-11","current":19.753645,"percent":0.928571,"low":19.106036,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"high":19.873689,"avg":19.470745,"sd":0.216526,"marketCap":13611556279.78},"quantilePoints":[{"date":"2025-05-30","current":19.76944,"twenty":19.76944,"median":19.76944,"eighty":19.76944,"marketCap":13505496352.43},{"date":"2025-06-06","current":19.324012,"twenty":19.535669,"median":19.692043,"eighty":19.76944,"marketCap":13350532994.37},{"date":"2025-06-13","current":19.308216,"twenty":19.137627,"median":19.324012,"eighty":19.722054,"marketCap":13371262392.6},{"date":"2025-06-20","current":19.245035,"twenty":19.160372,"median":19.387193,"eighty":19.674036,"marketCap":13211518175.96},{"date":"2025-06-27","current":19.308216,"twenty":19.224185,"median":19.382455,"eighty":19.560942,"marketCap":13348226238.04},{"date":"2025-07-03","current":19.469329,"twenty":19.242508,"median":19.399829,"eighty":19.679723,"marketCap":13533023992.92},{"date":"2025-07-11","current":19.753645,"twenty":19.282944,"median":19.43142,"eighty":19.706259,"marketCap":13611556279.78}],"updateTime":1752392708047}}}